MedTrace Logo

IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine

NCT02664116 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-02-03

No results posted yet for this study

Summary

This research will be conducted to see if the oral drug Cambia is as effective in relieving severe migraine headaches as the injectable drug ketorolac.

Conditions

  • Migraine Headache

Interventions

DRUG

Diclofenac postassium powder for oral solution and placebo injection

Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose

DRUG

Ketorolac intramuscular injection and placebo oral solution

ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose

Sponsors & Collaborators

  • Depomed

    collaborator INDUSTRY

  • Scripps Health

    lead OTHER

Principal Investigators

  • Emily Rubenstein Engel, MD · Scripps Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02664116 on ClinicalTrials.gov